LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

UNH

339.07

+3.56%↑

NVS

132.26

+1.57%↑

ABT

128.82

+1.49%↑

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

UNH

339.07

+3.56%↑

NVS

132.26

+1.57%↑

ABT

128.82

+1.49%↑

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

UNH

339.07

+3.56%↑

NVS

132.26

+1.57%↑

ABT

128.82

+1.49%↑

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

UNH

339.07

+3.56%↑

NVS

132.26

+1.57%↑

ABT

128.82

+1.49%↑

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

UNH

339.07

+3.56%↑

NVS

132.26

+1.57%↑

ABT

128.82

+1.49%↑

Strona główna・Stock List・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Closed

4.83 2.99

Buy Sell

Overview

Share price change

24h

Current

Min

4.6

Max

4.86

Key metrics
By Trading Economics
Income	27M 2.5M
Sales	9M 11M
Profit margin	23.494
Employees	44
EBITDA	27M 2.6M

Dividends
By Dow Jones
Next Earnings	12 lis 2025

Market Stats
By TradingEconomics
Market Cap	238M 878M
Previous open	1.84
Previous close	4.83

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

3.255 / 3.365 Support & Resistance

Arbutus Biopharma Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lis 2025, 23:59 UTC

Earnings

Singtel's 1st Half Net Profit Surges

11 lis 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 lis 2025, 22:21 UTC

Earnings

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 lis 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 lis 2025, 23:44 UTC

Earnings

Singtel's 1H Net Profit Surges

11 lis 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 lis 2025, 23:18 UTC

Earnings

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 lis 2025, 23:15 UTC

Earnings

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 lis 2025, 23:14 UTC

Earnings

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 lis 2025, 23:12 UTC

Earnings

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 lis 2025, 23:11 UTC

Earnings

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 lis 2025, 23:10 UTC

Earnings

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 lis 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

11 lis 2025, 21:46 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 lis 2025, 21:41 UTC

Earnings

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 lis 2025, 21:40 UTC

Earnings

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: Final Dividend 49 Australian Cents/Share

11 lis 2025, 21:37 UTC

Earnings

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 lis 2025, 21:36 UTC

Earnings

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 lis 2025, 21:35 UTC

Earnings

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Adj EPS 79c >ALC

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Rev $2.61B >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q EPS 48c >ALC.EB

Peer Comparison

Price change

Arbutus Biopharma Corp Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Arbutus Biopharma Corp - Dist in the past 3 months.

Technical Score

By Trading Central

3.255 / 3.365Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.